Changes in women's attitudes towards and use of hormone therapy after HERS and WHI

Maturitas

Volumn 52, Issue 1, 2005, Pages 11-17

  Hoffmann, Mikael ^a   Hammar, Mats ^a   Kjellgren, Karin I ^b   Lindh Åstrand, Lotta ^a   Brynhildsen, Jan ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Communication; Communications media mass media; Concordance (patient compliance); Hormone replacement therapy; Risk

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; ATTITUDE; CLIMACTERIUM; COMMUNITY; COMPARATIVE STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DATA BASE; DRUG USE; FEMALE; HEALTH CARE PERSONNEL; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MASS MEDIUM; MEDICAL INFORMATION; MENOPAUSAL SYNDROME; POSTAL MAIL; PUBLICATION; QUESTIONNAIRE; RISK; RISK BENEFIT ANALYSIS; SWEDEN; TELECOMMUNICATION; TELEVISION;

COMMUNICATIONS MEDIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; SWEDEN; WOMEN'S HEALTH;

EID: 24144492133     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.06.003     Document Type: Article

References (23)

1. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women heart and estrogen/progestin replacement study (HERS) research group JAMA 280 1998 605 613
2. D. Grady, D. Herrington, and V. Bittner Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II) JAMA 288 2002 49 57
3. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial JAMA 288 2002 321 333
4. J.E. Manson, J. Hsia, and K.C. Johnson Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
5. S. Wassertheil-Smoller, S.L. Hendrix, and M. Limacher Effect of estrogen plus progestin on stroke in postmenopausal women: the women's health initiative: a randomized trial JAMA 289 2003 2673 2684
6. V. Beral Breast cancer and hormone-replacement therapy in the million women study Lancet 362 2003 419 427
7. Hormone therapy: The American College of Obstetricians and Gynecologists (ACOG). Obstet Gynecol 2004;104.
8. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004;11:11-33.
9. EMEA public statement on recent publications regarding hormone replacement. London: European Agency for the Evaluation of Medicinal Products; 2004.
10. M.H. Moen, S.T. Nilsen, and O.E. Iversen A significant change in Norwegian gynecologist's attitude to hormone therapy is observed after the results of the Women's Health Initiative study Acta Obstet Gynecol Scand 84 2005 92 93
11. A.L. Hersh, M.L. Stefanick, and R.S. Stafford National use of postmenopausal hormone therapy: annual trends and response to recent evidence JAMA 291 2004 47 53
12. D.S.M. Buist, K.M. Newton, and D.L. Miglioretti Hormone therapy prescribing patterns in the United States Obstet Gynecol 104 2004 1042 1050
13. B. Ettinger, D. Grady, A.N. Tosteson, A. Pressman, and J.L. Macer Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy Obstet Gynecol 102 2003 1225 1232
14. E.S. Breslau, W.W. Davis, and L. Doner The hormone therapy dilemma: women respond J Am Med Womens Assoc 58 2003 33 43
15. D.L. Streiner, and G.R. Norman Health measurement scales: a practical guide to their development and use 3rd ed. 2003 Oxford University Press Oxford
16. Medical Products Agency's guidelines on authorization to place natural remedies on the market; Resolved on October 2nd, 1995.
17. The WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/.
18. A.I. Wertheimer The defined daily dose system (DDD) for drug utilization review Hosp Pharm 21 1986 233 234 9-41, 58
19. B. Lawton, S. Rose, D. McLeod, and A. Dowell Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users BMJ 327 2003 845 846
20. J.S. Haas, C.P. Kaplan, E.P. Gerstenberger, and K. Kerlikowske Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results Ann Intern Med 140 2004 184 188
21. S.R. Majumdar, E.A. Almasi, and R.S. Stafford Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative JAMA 292 2004 1983 1988
22. J.L. Nilsson, H. Johansson, and M. Wennberg Large differences between prescribed and dispensed medicines could indicate undertreatment Drug Inform J 29 1995 1243 1246
23. A.H. MacLennan, A.W. Taylor, and D.H. Wilson Hormone therapy use after the Women's Health Initiative Climacteric 7 2004 138 142